Topoisomerase II α Gene as a Marker for Prognostic Prediction of Hepatocellular Carcinoma: A Bioinformatics Analysis
To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HC...
Saved in:
Published in | Chinese medical sciences journal Vol. 37; no. 4; pp. 331 - 339 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
China
Elsevier B.V
31.12.2022
Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients.
We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis.
TOP2α and its co-expression genes were highly expressed in HCC (P < 0.001) and detrimental to overall survival of HCC patients (P < 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.00194S). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.026S) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.4S9, P < 0.01), CD8+T cell (r = 0.312, P < 0.01), CD4+T cell (r = 0.370, P < 0.01), macrophage (r = 0.459, P < 0.01), neutrophil (r = 0.405, P < 0.01), and dendritic cell (r = 0.473, P < 0.01) in HCC. The CD8+T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P < 0.05), and CD4+T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P < 0.05)
TOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC. |
---|---|
AbstractList | Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. Results TOP2α and its co-expression genes were highly expressed in HCC (P < 0.001) and detrimental to overall survival of HCC patients (P < 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.001945). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.0265) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.459, P < 0.01), CD8+ T cell (r = 0.312, P < 0.01), CD4+ T cell (r = 0.370, P < 0.01), macrophage (r = 0.459, P < 0.01), neutrophil (r = 0.405, P < 0.01), and dendritic cell (r = 0.473, P < 0.01) in HCC. The CD8+ T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P < 0.05), and CD4+ T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P < 0.05) Conclusion TOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC. Objective To investigate the expression of Ⅱ ( ) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by plotter analysis. Results and its co-expression genes were highly expressed in HCC ( < 0.001) and detrimental to overall survival of HCC patients ( < 0.001). and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, = 0.001945). and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival ( = 0.0247) and disease-free survival ( = 0.0265) of HCC patients. High expression was positively correlated with the infiltration of B cell ( = 0.459, < 0.01), CD8 T cell ( = 0.312, < 0.01), CD4 T cell ( = 0.370, < 0.01), macrophage ( = 0.459, < 0.01), neutrophil ( = 0.405, < 0.01), and dendritic cell ( = 0.473, < 0.01) in HCC. The CD8 T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all < 0.05), and CD4 T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all < 0.05). Conclusion may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC. Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. Results TOP2α and its co-expression genes were highly expressed in HCC (P< 0.001) and detrimental to overall survival of HCC patients (P< 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.001945). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.0265) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.459, P< 0.01), CD8+ T cell (r = 0.312, P< 0.01), CD4+ T cell (r = 0.370, P< 0.01), macrophage (r = 0.459, P< 0.01), neutrophil (r = 0.405, P< 0.01), and dendritic cell (r = 0.473, P< 0.01) in HCC. The CD8+ T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P< 0.05), and CD4+ T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P< 0.05). ConclusionTOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. Results TOP2α and its co-expression genes were highly expressed in HCC (P< 0.001) and detrimental to overall survival of HCC patients (P< 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.001945). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.0265) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.459, P< 0.01), CD8+ T cell (r = 0.312, P< 0.01), CD4+ T cell (r = 0.370, P< 0.01), macrophage (r = 0.459, P< 0.01), neutrophil (r = 0.405, P< 0.01), and dendritic cell (r = 0.473, P< 0.01) in HCC. The CD8+ T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P< 0.05), and CD4+ T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P< 0.05). ConclusionTOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC. To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. TOP2α and its co-expression genes were highly expressed in HCC (P < 0.001) and detrimental to overall survival of HCC patients (P < 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.00194S). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.026S) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.4S9, P < 0.01), CD8+T cell (r = 0.312, P < 0.01), CD4+T cell (r = 0.370, P < 0.01), macrophage (r = 0.459, P < 0.01), neutrophil (r = 0.405, P < 0.01), and dendritic cell (r = 0.473, P < 0.01) in HCC. The CD8+T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P < 0.05), and CD4+T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P < 0.05) TOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC. |
Author | Ma, Junjie An, Shaoguang Yu, Peng Chen, Yunfan Tao, Heng Zhang, Haoxuan Yang, Yue Zhang, Lei Lu, Jin |
AuthorAffiliation | School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China;Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China |
AuthorAffiliation_xml | – name: School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China;Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China |
Author_xml | – sequence: 1 givenname: Jin surname: Lu fullname: Lu, Jin organization: School of Basic Medicine, Bengbu, Anhui 233030, China – sequence: 2 givenname: Shaoguang surname: An fullname: An, Shaoguang organization: Clinical Medical College; Bengbu Medical College, Bengbu, Anhui 233030, China – sequence: 3 givenname: Junjie surname: Ma fullname: Ma, Junjie organization: Clinical Medical College; Bengbu Medical College, Bengbu, Anhui 233030, China – sequence: 4 givenname: Yue surname: Yang fullname: Yang, Yue organization: Department of Otolaryngology, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China – sequence: 5 givenname: Lei surname: Zhang fullname: Zhang, Lei organization: Department of Surgical Oncology, Second Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China – sequence: 6 givenname: Peng surname: Yu fullname: Yu, Peng organization: School of Basic Medicine, Bengbu, Anhui 233030, China – sequence: 7 givenname: Heng surname: Tao fullname: Tao, Heng organization: School of Basic Medicine, Bengbu, Anhui 233030, China – sequence: 8 givenname: Yunfan surname: Chen fullname: Chen, Yunfan organization: School of Basic Medicine, Bengbu, Anhui 233030, China – sequence: 9 givenname: Haoxuan surname: Zhang fullname: Zhang, Haoxuan email: 0100197@bbmc.edu.cn organization: School of Basic Medicine, Bengbu, Anhui 233030, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36647592$$D View this record in MEDLINE/PubMed |
BookMark | eNptkc9u1DAQh30oon9AvAHyDS6BsZ04G27LqrQrFbWHcrZmnXHlJbEXOwH1sfoiPBNutwUJONmyvp9n5ptjdhBiIMZeCXgn607Ce4AaQB-wIwEgqk529SE7znkL5VUs6ufsUGldt00nj9h8HXfR5zhSwkx8veY_7_gZBeKYOfLPmL5S4i4mfpXiTYh58rZcqfd28jHw6Pg57XCKloZhHjDxFSbrQxzxA1_yjz76UNIjllzmy4DDbfb5BXvmcMj08vE8YV8-nV6vzquLy7P1anlRWQVKV1S3tV5oaEA4aKHVmxZ1bTvX9koosWg2WpSRZNcBNapTTU-bxuECnOgloVMn7M3-3x8YHIYbs41zKj1kY8e8NSRBygdZhXy7J3cpfpspT2b0-X4mDBTnbGRblCmhm6agrx_ReTNSb3bJj5huzZPUP1Vtijkncr8RAeZhRQaeqlZ_kdZPeC92SuiH__Biz1OR9t1TMtl6CrasI5GdTB_9P5lfeSWiEA |
CitedBy_id | crossref_primary_10_1186_s12967_024_05576_y |
ContentType | Journal Article |
Copyright | 2022 Chinese Academy Medical Sciences Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
Copyright_xml | – notice: 2022 Chinese Academy Medical Sciences – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
CorporateAuthor | 3蚌埠医学院 临床医学院, 安徽, 蚌埠 233030 3Clinical Medical College, Bengbu Medical College, Bengbu, Anhui 233030, China 4蚌埠医学院 第一附属医院耳鼻喉科, 安徽, 蚌埠 233030 4Department of Otolaryngology, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China 5蚌埠医学院 第二附属医院肿瘤外科, 安徽, 蚌埠 233030 5Department of Surgical Oncology, Second Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China 1蚌埠医学院 基础医学院, 安徽, 蚌埠 233030 1School of Basic Medicine, Bengbu Medical College, Bengbu, Anhui 233030, China 2蚌埠医学院 数字医学与智慧健康安徽省重点实验室, 安徽, 蚌埠 233030 2Anhui Key Laboratory of Computational Medicine and Intelligent Health, Bengbu Medical College, Bengbu, Anhui 233030, China |
CorporateAuthor_xml | – name: 1蚌埠医学院 基础医学院, 安徽, 蚌埠 233030 1School of Basic Medicine, Bengbu Medical College, Bengbu, Anhui 233030, China – name: 5蚌埠医学院 第二附属医院肿瘤外科, 安徽, 蚌埠 233030 5Department of Surgical Oncology, Second Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China – name: 4蚌埠医学院 第一附属医院耳鼻喉科, 安徽, 蚌埠 233030 4Department of Otolaryngology, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China – name: 2蚌埠医学院 数字医学与智慧健康安徽省重点实验室, 安徽, 蚌埠 233030 2Anhui Key Laboratory of Computational Medicine and Intelligent Health, Bengbu Medical College, Bengbu, Anhui 233030, China – name: 3蚌埠医学院 临床医学院, 安徽, 蚌埠 233030 3Clinical Medical College, Bengbu Medical College, Bengbu, Anhui 233030, China |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 2B. 4A8 92I 93N PSX TCJ |
DOI | 10.24920/004006 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EndPage | 339 |
ExternalDocumentID | cmsj_e202204006 36647592 10_24920_004006 S100192942300007X |
Genre | Journal Article |
GroupedDBID | --- --K -05 -0E -SE -S~ .~1 0R~ 1B1 1~. 1~5 29B 2B. 2C~ 4.4 457 4G. 53G 5GY 5VR 5VS 5XA 5XF 5XL 7-5 71M 92F 92I 92M 93N 93R 9D9 9DE AAEDT AALRI AAQFI AAXUO ABBQC ABKZE ADMUD AEKER AFTJW AFUIB AGYEJ AITUG AJRQY ALMA_UNASSIGNED_HOLDINGS CAJEE CAJUS CCEZO CHBEP CIEJG CW9 DU5 EBS EJD EP2 EP3 FA0 FDB FNPLU GBLVA HZ~ J1W JUIAU M41 MO0 N9A O-L O9- OZT P-8 P-9 PC. Q-- Q-4 Q38 R-E RIG ROL RT5 S.. SDF SES T8U TCJ TGQ U1F U1G U5E U5O WFFXF AAYXX ABWVN ACRPL ADNMO AIGII CITATION AAXDM CGR CUY CVF ECM EIF NPM 7X8 4A8 PSX |
ID | FETCH-LOGICAL-c3036-e4746860501f07076b7a64c9f7d313185b610612990e53935deb5fa80f1d2eaf3 |
IEDL.DBID | .~1 |
ISSN | 1001-9294 |
IngestDate | Thu May 29 03:54:36 EDT 2025 Fri Jul 11 07:43:13 EDT 2025 Thu Jan 02 22:52:10 EST 2025 Tue Jul 01 01:55:48 EDT 2025 Thu Apr 24 22:54:23 EDT 2025 Fri Feb 23 02:38:27 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | overall survival disease-free survival topoisomerase II a bioinformatics analysis hepatocellular carcinoma topoisomeraseⅡα |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3036-e4746860501f07076b7a64c9f7d313185b610612990e53935deb5fa80f1d2eaf3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://cmsj.cams.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3594 |
PMID | 36647592 |
PQID | 2766431655 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | wanfang_journals_cmsj_e202204006 proquest_miscellaneous_2766431655 pubmed_primary_36647592 crossref_primary_10_24920_004006 crossref_citationtrail_10_24920_004006 elsevier_sciencedirect_doi_10_24920_004006 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-Dec-31 |
PublicationDateYYYYMMDD | 2022-12-31 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-Dec-31 day: 31 |
PublicationDecade | 2020 |
PublicationPlace | China |
PublicationPlace_xml | – name: China |
PublicationTitle | Chinese medical sciences journal |
PublicationTitleAlternate | Chin Med Sci J |
PublicationTitle_FL | Chinese Medical Sciences Journal |
PublicationYear | 2022 |
Publisher | Elsevier B.V Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China |
Publisher_xml | – name: Elsevier B.V – name: School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China – name: Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China |
References | Meyerovich, Goykhman, Nakache (bib137) 2019; 51 Liang, Zhu, Wang (bib134) 2019; 9 Huang, Wong, Tsui (bib138) 2019; 19 Almeida, René Gerhard, Dina Leitao (bib148) 2014; 210 Zhou, Li, Mao (bib146) 2019; 28 Schmidt (bib153) 2019; 3 Ji, Hu, Zhang (bib136) 2019; 11 Connell, Harding, Shia (bib143) 2016; 5 Sun, Yao, Song (bib144) 2017; 133 Visconti, Delia Monica, Grieco (bib150) 2016; 35 Utama, Patriawan (bib154) 2019; 7 Zeng, Liu, Dai (bib140) 2019; 19 Ghisoni, Maggiorotto, Borella (bib142) 2019; 12 Iwanaga (bib145) 2013; 40 Guillén, Prieto, Jiménez de Ory (bib152) 2019; 14 Rocha, Farias, Lima (bib139) 2019; 199 Nuncia-Cantarero, Martinez-Canales, Andrés-Pretel (bib141) 2018; 168 Dominguezbrauer, Thu, Mason (bib149) 2015; 60 Kang, Song, Du (bib151) 2016; 5 Skill, Butler, O’Brien (bib135) 2019; 51 Chen, Chien, Chen (bib147) 2017; 96 |
References_xml | – volume: 51 start-page: 1867 year: 2019 end-page: 1873 ident: bib137 article-title: Resection publication-title: Transplant Proc – volume: 51 start-page: 1907 year: 2019 end-page: 1912 ident: bib135 article-title: Financial burden of liver transplant publication-title: Transplant Proc – volume: 19 start-page: 789 year: 2019 ident: bib138 article-title: Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma publication-title: BMC cancer – volume: 35 start-page: 153 year: 2016 ident: bib150 article-title: Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword publication-title: Clin Cancer Res – volume: 210 start-page: 675 year: 2014 end-page: 679 ident: bib148 article-title: Topoisomerase II-alfa gene as a predictive marker of response to anthracy-clines in breast cancer publication-title: Pathol Res Pract – volume: 14 start-page: e0220552 year: 2019 ident: bib152 article-title: Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children publication-title: PloS One – volume: 96 start-page: e5582 year: 2017 ident: bib147 article-title: Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer publication-title: Medicine (Baltimore) – volume: 40 start-page: 1475 year: 2013 end-page: 1487 ident: bib145 article-title: Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011 publication-title: Gan To Kagaku Ryoho – volume: 199 start-page: 110725 year: 2019 ident: bib139 article-title: Computational studies, design and synthesis of Pd(II)-based complexes: allosteric inhibitors of the human topoisomerase-II publication-title: J Inorg Biochem – volume: 11 start-page: 4290 year: 2019 end-page: 4302 ident: bib136 article-title: Long non-coding RNA DSCAM-AS1 accelerates the progression of hepatocellular carcinoma publication-title: Am J Transí Res – volume: 168 start-page: 613 year: 2018 end-page: 623 ident: bib141 article-title: Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer publication-title: Breast Cancer Res Treat – volume: 60 start-page: 524 year: 2015 end-page: 536 ident: bib149 article-title: Targeting mitosis in cancer: emerging strategies publication-title: Mol Cell – volume: 12 start-page: 17 year: 2019 ident: bib142 article-title: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers publication-title: J Ovarian Res – volume: 5 start-page: 66 year: 2016 ident: bib143 article-title: Combined intrahepatic cholan-giocarcinoma and hepatocellular carcinoma publication-title: Chin Clin Oncol – volume: 19 start-page: 604 year: 2019 ident: bib140 article-title: Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms publication-title: BMC cancer – volume: 3 start-page: 1 year: 2019 end-page: 12 ident: bib153 article-title: Identification of novel respiratory syncytial virus CD4 and CD8 T cell epitopes in C57BL/6 mice publication-title: Immunohorizons – volume: 28 start-page: 76S year: 2019 end-page: 86S ident: bib146 article-title: Screening hub genes as prognostic biomarkers of hepatocellular carcinoma by bioinformatics analysis publication-title: Cell Transplant – volume: 5 start-page: 17873 year: 2016 ident: bib151 article-title: PTEN stabilizes TOP2A and regulates the DNA decatenation publication-title: Sci Rep – volume: 133 start-page: 1 year: 2017 end-page: 10 ident: bib144 article-title: Autophagy antagonizes apop-tosis induced by flavan enantiomers from Daphne giraldii in hepatic carcinoma cells publication-title: Eur J Med Chem – volume: 7 start-page: 1803 year: 2019 end-page: 1807 ident: bib154 article-title: Correlation of CD4/CD8 ratio with carotid intima-media layer thickness in HIV/AIDS patients at Sanglah General Hospital, Bali, Indonesia publication-title: Open Access Maced J Med Sci – volume: 9 start-page: 11580 year: 2019 ident: bib134 article-title: Evaluation of AGP fucosylation as a marker for hepatocellular carcinoma of three different etiologies publication-title: Sci Rep |
SSID | ssj0006184 |
Score | 2.2658508 |
Snippet | To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients.
We used... Objective To investigate the expression of Ⅱ ( ) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used... Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients.... |
SourceID | wanfang proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 331 |
SubjectTerms | bioinformatics analysis Biomarkers, Tumor - genetics Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - genetics CD8-Positive T-Lymphocytes Computational Biology disease-free survival DNA Topoisomerases, Type II - genetics hepatocellular carcinoma Humans Liver Neoplasms - diagnosis Liver Neoplasms - genetics overall survival Prognosis topoisomerase II a |
Title | Topoisomerase II α Gene as a Marker for Prognostic Prediction of Hepatocellular Carcinoma: A Bioinformatics Analysis |
URI | https://dx.doi.org/10.24920/004006 https://www.ncbi.nlm.nih.gov/pubmed/36647592 https://www.proquest.com/docview/2766431655 https://d.wanfangdata.com.cn/periodical/cmsj-e202204006 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NitswEBbLwpZeSjf9S9stUyg5lHUTO7Jk720JXbKFLYFmITchyVJJ6VohTg659J36In2mamR50xJ66M3YsiU0o5mRNd83hLyjqWa24joZF1onNLN-zSmqk7TyvppKZYtQzufmM5ve0k-LfHFEJh0WBtMqo-1vbXqw1vHOMM7mcLVcDr-kITwpfTwQzuMWiGCnHLX8w499mgcWNAknnn7bjK0jcJaW2WgYNJj9yyMdRpwB2FNbWX_9wwddPSaPYvAIl-34TsmRqXvkpC0nueuRBzfxoLxHBrOWknp3DvM9wqo5hwHM9mTVuydkO3crt2wc_ptqDFxfw6-fgFzUIBuQgFAeswYf2cJs7TApz3_GX2JHKFJwFqbeo20cngBgSitMsDpR7e7kBVyCH1ukZsXuoaNAeUpurz7OJ9MklmJINPq4xFBOWeG3PqPUIkEQU1wyqkvLq3GKAGzFcG-Jvs3kiPatjMqtLEY2rTIj7fgZOa5dbV4QsJL7kMayTPtQLFemUFyn3BqtylSOtO6TQScOoSNPOZbL-C78fiXITbRy6xO4b7hqqTkOm7zv5Cn-0irhHcZh47edxIVfYzhtsjZu24iMM4aUAXneJ89bVbjvcewf8bzM_GiibohoBRqh75pvwmQIZsYOXv7PaF6Rh_hiyyn5mhxv1ltz5uOfjXoTFPw34qkBRA |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWRTwuCMqrPAcJekAb2qSOkyBxWC2sWna7qkRX6s3rODYqYpOqaYV64T8h_ge_iZnE2YIqDhz2FiWWbXnGM5_jmW8Ye8l9LWwWaa8fa-3xwOKeS7n2_Ax9NVepjatyPqMTMTjlH6fhdIf9bHJhKKzS2f7aplfW2r3putXszmez7ie_gicJ4oHqPm7qIiuPzPobntvKd8P3KORXQXD4YXIw8FxpAU-TzfYMj7iIEcr3fEuENyKNlOA6sVHW9ymhOBV0ViJbbULKXs1MGloV96yfBUbZPvZ7hV3laC6obMKb75u4EqqgUl2x4jmdpucydXkS9LrVlhH_coHbELfKJMqtyj__4fQOb7NbDq3Cfr0gd9iOyVvsWl2_ct1i10fuZr7FOuOaA3u9B5NNSle5Bx0Yb9ix13fZalLMi1lZ0M-w0sBwCL9-AJFfgypBAeUOmQUglIbxoqAoQOwGH2kg0iEoLAzQhS4LunKgGFo4oHJIeXGu3sI-4NwcFywNDw3nyj12eikCus928yI3DxlYFSGGsiLQiP3C1MRppP3IGp0mvupp3WadRhxSO2J0qs_xVeIBqZKbrOXWZnDRcF5zgWw3ed3IU_6lxhI91HbjF43EJW5qWjaVm2JVyiASgjgKwrDNHtSqcDFiHz9FYRLgbJxuSGd2SqnPyy_SBJQ9TQM8-p_ZPGc3BpPRsTwenhw9Zjepk5rQ8gnbXS5W5imCr2X6rFJ2YGeXvbt-A86tO9Y |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Topoisomerase+%E2%85%A1%CE%B1+Gene+as+a+Marker+for+Prognostic+Prediction+of+Hepatocellular+Carcinoma%3A+A+Bioinformatics+Analysis&rft.jtitle=Chinese+medical+sciences+journal&rft.au=Lu%2C+Jin&rft.au=An%2C+Shao-Guang&rft.au=Ma%2C+Jun-Jie&rft.au=Yang%2C+Yue&rft.date=2022-12-31&rft.issn=1001-9294&rft.volume=37&rft.issue=4&rft.spage=331&rft_id=info:doi/10.24920%2F004006&rft.externalDBID=NO_FULL_TEXT |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fcmsj-e%2Fcmsj-e.jpg |